Table 3.
Current AHA use among patients with type 2 diabetes who were hospitalized for Fournier’s gangrene (cases) and matched controls
| Treatmenta | Overall | Male patients | Female patients | |||
|---|---|---|---|---|---|---|
| Cases (N = 216) | Controls (N = 1296) | Cases (N = 201) | Controls (N = 1206) | Cases (N = 15) | Controls (N = 90) | |
| SGLT2i (with or without other AHAs) | 9 (4.2%) | 100 (7.7%) | 8 (4.0%) | 85 (7.1%) | 1 (6.7%) | 15 (16.7%) |
| Two or more non-SGLT2i AHAs or insulin alone | 97 (44.9%) | 474 (36.6%) | 89 (44.3%) | 447 (37.1%) | 8 (53.3%) | 27 (30.0%) |
| Two or more non-SGLT2i AHAs | 59 (27.3%) | 411 (31.7%) | 55 (27.4%) | 385 (31.9%) | 4 (26.7%) | 26 (28.9%) |
| Insulin alone | 38 (17.6%) | 63 (4.9%) | 34 (16.9%) | 62 (5.1%) | 4 (26.7%) | 1 (1.1%) |
| Single AHAs excluding insulin or no current exposure | 110 (50.9%) | 722 (55.7%) | 104 (51.7%) | 674 (55.9%) | 6 (40.0%) | 48 (53.3%) |
aAs defined in “Methods”